The Sunday before last, the Star Tribune published a front-page story laying out how Medtronic, one the area’s highest profile corporations, “misfiled” a report on adverse reactions to the company’s lucrative but problematic bone fusion device, Infuse.
Reported by Jim Spencer, Joe Carlson and Mary Jo Webster, and edited by Thom Kupper of the paper’s business section, ?the piece?, “a Question of Risk,” drew an immediate and predictable response from Medtronic, ?which the Strib published?, asserting among other things that, “The article makes insinuations that are false, and fails to include important information regarding the [retrospective chart review] RCR and Medtronic’s actions. Medtronic provided the Star Tribune an extensive account of what transpired around the RCR, both in person and in writing, which was largely omitted from the article.”
